Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
Phase of Trial: Phase III
Latest Information Update: 22 Feb 2019
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Fludarabine; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 13 Jul 2018 Planned End Date changed from 1 Oct 2020 to 1 Oct 2021.
- 13 Jul 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.
- 13 Jul 2018 Status changed from not yet recruiting to recruiting.